Flow cytometric analysis of Human CD123 expression on human PBMC (human peripheral blood mononuclear cell). Human PBMC were stained with Alexa Fluor® 488 Mouse Anti-Human HLA/DR antibody and either Alexa Fluor® 700 Mouse IgG2a, κ Isotype Control (Left panel) or SDT Alexa Fluor® 700 Mouse Anti-Human CD123 Antibody (Right panel) at 1.25 μl/test. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
Alexa Fluor® 700 Mouse Anti-Human CD123 Antibody (S-R442)
Alexa Fluor® 700 Mouse Anti-Human CD123 Antibody (S-R442)
Price:
Regular price
$160 USD
Regular price
Sale price
$160 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD123 |
| Synonyms | Interleukin-3 receptor subunit alpha; IL-3 receptor subunit alpha; IL-3R subunit alpha; IL-3R-alpha; IL-3RA; IL3R; IL3RA |
| Location | Cell membrane |
| Accession | P26951 |
| Clone Number | S-R442 |
| Antibody Type | Mouse mAb |
| Isotype | IgG2a,k |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | Human PBMC |
| Purification | Protein A |
| Concentration | 0.2 mg/ml |
| Conjugation | Alexa Fluor® 700 |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1.25μl per million cells in 100μl volume | Hu |
Background
CD123, also known as interleukin-3 receptor alpha chain (IL-3Rα), is a 75 kDa type-I transmembrane glycoprotein that pairs with the common β-subunit (CD131) to form the high-affinity IL-3 receptor, triggering JAK/STAT, PI3K/AKT and MAPK cascades that drive proliferation, survival and differentiation of hematopoietic stem/progenitor cells, plasmacytoid dendritic cells, basophils and eosinophils; it is constitutively over-expressed on blasts and leukemic stem cells in >90 % of acute myeloid leukemias, B-ALL and blastic plasmacytoid dendritic cell neoplasm, making it a key diagnostic biomarker and a validated target for monoclonal antibodies, antibody-drug conjugates, bispecific T-cell engagers and CAR-T/CAR-NK therapies.
Picture
Picture
FC
